Gain expert insights on when to use therapeutic drug monitoring proactively to improve the efficacy of biologic therapy for inflammatory bowel disease (IBD) and reactively to guide decision-making following primary nonresponse or secondary loss of response to a biologic.
Take advantage of our new, free CME program developed in collaboration with AGA and Clinical Care Options, Advances in IBD Precision Medicine With Therapeutic Drug Monitoring.
Although tumor necrosis factor (TNF) inhibitors have revolutionized the treatment of IBD, they are associated with high rates of both primary nonresponse, in which patients start therapy but don’t respond, and secondary nonresponse, in which patients do respond initially but have a secondary loss of response over time.
This new enduring program offers three different options:
